Abstract
Growth factors (GF) are reported to play an important role in the therapy of myelodisplastic syndromes (MDS). After in vitro administration a consistent group of MDS may respond to GF but the possibility of differentiation, regulation or expansion of myelodisplastic clones following GF therapy is still a question to be answered as their optimum dose and combinations. To validate if in vivo treatment with GF, may promote the regulation or the recovery of myelopoiesis and/or modify the clonality of the responses, we gave G-CSF after intensive chemotherapy in high risk MDS and acute Leukemia evolving from MDS patients. According to our data the use of G-CSF after intensive chemotherapy may improve the CR rate without increase of leukemic transformation. However the answer were clonal and the remission duration remained very short so we suggest to utilize this time to perform other therapeutic strategies such as, when possible, the BMT.
| Original language | English |
|---|---|
| Pages (from-to) | 35-40 |
| Number of pages | 6 |
| Journal | Leukemia and Lymphoma |
| Volume | 26 |
| Issue number | SUPPL. 1 |
| Publication status | Published - 1997 |
Fingerprint
Keywords
- Growth factors
- Myelodisplastic syndromes
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Growth factors in the therapy of myelodisplasia : Biological aspects. / Bonfichi, Maurizio; Astori, Cesare; Alessandrino, Emilio Paolo; Balduini, P. B A; Castagnola, Carlo; Brusamolino, Ercole; Pagnucco, Guido; Canevari, Angelo; Trucco, Paola; Bernasconi, Carlo.
In: Leukemia and Lymphoma, Vol. 26, No. SUPPL. 1, 1997, p. 35-40.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Growth factors in the therapy of myelodisplasia
T2 - Biological aspects
AU - Bonfichi, Maurizio
AU - Astori, Cesare
AU - Alessandrino, Emilio Paolo
AU - Balduini, P. B A
AU - Castagnola, Carlo
AU - Brusamolino, Ercole
AU - Pagnucco, Guido
AU - Canevari, Angelo
AU - Trucco, Paola
AU - Bernasconi, Carlo
PY - 1997
Y1 - 1997
N2 - Growth factors (GF) are reported to play an important role in the therapy of myelodisplastic syndromes (MDS). After in vitro administration a consistent group of MDS may respond to GF but the possibility of differentiation, regulation or expansion of myelodisplastic clones following GF therapy is still a question to be answered as their optimum dose and combinations. To validate if in vivo treatment with GF, may promote the regulation or the recovery of myelopoiesis and/or modify the clonality of the responses, we gave G-CSF after intensive chemotherapy in high risk MDS and acute Leukemia evolving from MDS patients. According to our data the use of G-CSF after intensive chemotherapy may improve the CR rate without increase of leukemic transformation. However the answer were clonal and the remission duration remained very short so we suggest to utilize this time to perform other therapeutic strategies such as, when possible, the BMT.
AB - Growth factors (GF) are reported to play an important role in the therapy of myelodisplastic syndromes (MDS). After in vitro administration a consistent group of MDS may respond to GF but the possibility of differentiation, regulation or expansion of myelodisplastic clones following GF therapy is still a question to be answered as their optimum dose and combinations. To validate if in vivo treatment with GF, may promote the regulation or the recovery of myelopoiesis and/or modify the clonality of the responses, we gave G-CSF after intensive chemotherapy in high risk MDS and acute Leukemia evolving from MDS patients. According to our data the use of G-CSF after intensive chemotherapy may improve the CR rate without increase of leukemic transformation. However the answer were clonal and the remission duration remained very short so we suggest to utilize this time to perform other therapeutic strategies such as, when possible, the BMT.
KW - Growth factors
KW - Myelodisplastic syndromes
UR - http://www.scopus.com/inward/record.url?scp=7144235828&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7144235828&partnerID=8YFLogxK
M3 - Article
VL - 26
SP - 35
EP - 40
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - SUPPL. 1
ER -